broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K72951360-001-01-4 | ACH-000833 | RH30_SOFT_TISSUE | HTS002 | 1 | 0.041823 | 4.755363 | 0.683283 | 0.693382 | 0.448103 | 0.45641 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000833 |
BRD-K72951360-001-01-4 | ACH-000137 | 8MGBA_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.006656 | 2.204893 | 0.693127 | 0.657441 | 0.352177 | 0.354324 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000137 |
BRD-K72951360-001-01-4 | ACH-000632 | HS944T_SKIN | HTS002 | 1 | 0.00103 | 1.208615 | 0.651668 | 0.597865 | 0.202475 | 0.20282 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000632 |
BRD-K72951360-001-01-4 | ACH-000319 | MPP89_PLEURA | HTS002 | 1 | 0.010554 | 10.88647 | 0.091506 | 0.870484 | 2.807634 | 2.813142 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000319 |
BRD-K72951360-001-01-4 | ACH-000630 | YD8_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.061119 | 1.248087 | 0.675181 | 0.662892 | 0.309867 | 0.343988 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000630 |
BRD-K72951360-001-01-4 | ACH-000266 | SNU213_PANCREAS | HTS002 | 1 | 0.018313 | 2.449445 | 0.589658 | 0.693089 | 0.481419 | 0.488808 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000266 |
BRD-K72951360-001-01-4 | ACH-000047 | GCIY_STOMACH | HTS002 | 1 | 0.036175 | 1.659485 | 0.830075 | 0.657654 | 0.319085 | 0.333857 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000047 |
BRD-K72951360-001-01-4 | ACH-000273 | SF539_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.02495 | 7.091589 | 0.763671 | 0.68423 | 0.431675 | 0.434803 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000273 |
BRD-K72951360-001-01-4 | ACH-000682 | SNU1066_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | -0.001369 | 0.573962 | 0.714318 | 0.571096 | 0.171044 | 0.170231 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000682 |
BRD-K72951360-001-01-4 | ACH-000359 | MG63_BONE | HTS002 | 1 | -0.047075 | 0.691435 | 0.705631 | 0.621581 | 0.279931 | 0.245774 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000359 |
BRD-K72951360-001-01-4 | ACH-000846 | FADU_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.000311 | 0.971554 | 0.78189 | 0.522121 | 0.097068 | 0.09713 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000846 |
BRD-K72951360-001-01-4 | ACH-000804 | NB1_AUTONOMIC_GANGLIA | HTS002 | 1 | -0.002625 | 0.972617 | 0.947633 | 0.499433 | 0.077688 | 0.077271 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000804 |
BRD-K72951360-001-01-4 | ACH-000609 | SF126_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | -0.000313 | 0.798345 | 0.736678 | 0.536547 | 0.113094 | 0.113006 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000609 |
BRD-K72951360-001-01-4 | ACH-000974 | SNGM_ENDOMETRIUM | HTS002 | 1 | 0.003894 | 1.415019 | 0.512067 | 0.596096 | 0.195978 | 0.197064 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000974 |
BRD-K72951360-001-01-4 | ACH-000987 | MEWO_SKIN | HTS002 | 1 | 0.024705 | 8.940258 | 0.714039 | 0.713713 | 0.579297 | 0.58259 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000987 |
BRD-K72951360-001-01-4 | ACH-000787 | LXF289_LUNG | HTS002 | 1 | 0.051239 | 8.952091 | 0.812873 | 0.584789 | 0.143093 | 0.144832 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000787 |
BRD-K72951360-001-01-4 | ACH-000561 | TT_OESOPHAGUS | HTS002 | 1 | -0.00047 | 2.637988 | 0.763138 | 0.62829 | 0.271311 | 0.271215 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000561 |
BRD-K72951360-001-01-4 | ACH-000212 | CAL120_BREAST | HTS002 | 1 | -0.025111 | 1.316712 | 0.806747 | 0.726481 | 0.720127 | 0.69382 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000212 |
BRD-K72951360-001-01-4 | ACH-000753 | JMSU1_URINARY_TRACT | HTS002 | 1 | 0.010719 | 4.90439 | 0.56361 | 0.555144 | 0.127313 | 0.127877 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000753 |
BRD-K72951360-001-01-4 | ACH-000305 | ECGI10_OESOPHAGUS | HTS002 | 1 | 0.003916 | 1.186763 | 0.808718 | 0.580796 | 0.169345 | 0.17047 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000305 |
BRD-K72951360-001-01-4 | ACH-000138 | CFPAC1_PANCREAS | HTS002 | 1 | 0.01907 | 4.022765 | 0.574164 | 0.63323 | 0.265599 | 0.268179 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000138 |
BRD-K72951360-001-01-4 | ACH-000250 | KMRC20_KIDNEY | HTS002 | 1 | 0.115543 | 12.698068 | 0.543128 | 0.753155 | 0.666476 | 0.680412 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000250 |
BRD-K72951360-001-01-4 | ACH-000856 | CAL51_BREAST | HTS002 | 1 | 0.002816 | 0.950619 | 0.655027 | 0.625844 | 0.270288 | 0.271899 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000856 |
BRD-K72951360-001-01-4 | ACH-000046 | ACHN_KIDNEY | HTS002 | 1 | -0.000367 | 2.934229 | 0.841304 | 0.653481 | 0.34644 | 0.346354 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000046 |
BRD-K72951360-001-01-4 | ACH-000878 | HCC15_LUNG | HTS002 | 1 | 0.011168 | 0.861681 | 0.831935 | 0.570797 | 0.151294 | 0.155313 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000878 |
BRD-K72951360-001-01-4 | ACH-000766 | NCIH1648_LUNG | HTS002 | 1 | 0.007107 | 4.124871 | 0.904027 | 0.647498 | 0.318988 | 0.320097 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000766 |
BRD-K72951360-001-01-4 | ACH-000666 | NCIH1355_LUNG | HTS002 | 1 | 0.105937 | 8.809009 | 0.293518 | 0.829324 | 1.568439 | 1.61141 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000666 |
BRD-K72951360-001-01-4 | ACH-000014 | HS294T_SKIN | HTS002 | 1 | -0.002385 | 1.112183 | 0.537498 | 0.649513 | 0.340044 | 0.338592 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000014 |
BRD-K72951360-001-01-4 | ACH-000701 | RMUGS_OVARY | HTS002 | 1 | 0.058157 | 1.159285 | 0.376487 | 0.74187 | 0.728479 | 0.810477 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000701 |
BRD-K72951360-001-01-4 | ACH-000884 | MDAMB435S_SKIN | HTS002 | 1 | -0.001543 | 1.228546 | 0.484013 | 0.662499 | 0.383596 | 0.382635 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000884 |
BRD-K72951360-001-01-4 | ACH-000037 | S117_SOFT_TISSUE | HTS002 | 1 | 0.004717 | 6.945852 | 0.401765 | 0.694993 | 0.511069 | 0.511767 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000037 |
BRD-K72951360-001-01-4 | ACH-000504 | SNB75_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.024848 | 9.213411 | 0.52222 | 0.711746 | 0.567832 | 0.570982 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000504 |
BRD-K72951360-001-01-4 | ACH-000502 | TCCPAN2_PANCREAS | HTS002 | 1 | 0.028105 | 1.061659 | 0.711084 | 0.711444 | 0.586287 | 0.619122 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000502 |
BRD-K72951360-001-01-4 | ACH-000886 | NCIH2009_LUNG | HTS002 | 1 | 0.027104 | 3.119608 | 0.634542 | 0.576556 | 0.146456 | 0.149097 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000886 |
BRD-K72951360-001-01-4 | ACH-000035 | NCIH1650_LUNG | HTS002 | 1 | -0.027423 | 1.048558 | 0.373332 | 0.727788 | 0.757418 | 0.719813 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000035 |
BRD-K72951360-001-01-4 | ACH-000661 | WM1799_SKIN | HTS002 | 1 | 0.003712 | 1.254619 | 0.782553 | 0.513054 | 0.087171 | 0.08769 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000661 |
BRD-K72951360-001-01-4 | ACH-000391 | MHHES1_BONE | HTS002 | 1 | 0.00938 | 1.853944 | 0.709349 | 0.600653 | 0.20008 | 0.202134 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000391 |
BRD-K72951360-001-01-4 | ACH-000843 | HARA_LUNG | HTS002 | 1 | 0.003128 | 4.038335 | 0.536951 | 0.690413 | 0.491107 | 0.49187 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000843 |
BRD-K72951360-001-01-4 | ACH-000711 | JIMT1_BREAST | HTS002 | 1 | 0.011894 | 0.772011 | 0.56074 | 0.647336 | 0.339999 | 0.350769 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000711 |
BRD-K72951360-001-01-4 | ACH-000232 | U251MG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.047734 | 4.405732 | 0.680677 | 0.558872 | 0.111611 | 0.114182 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000232 |
BRD-K72951360-001-01-4 | ACH-000060 | PANC1005_PANCREAS | HTS002 | 1 | 0.001336 | 1.495138 | 0.553737 | 0.676209 | 0.432721 | 0.433496 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000060 |
BRD-K72951360-001-01-4 | ACH-000322 | HT144_SKIN | HTS002 | 1 | 0.003597 | 0.880026 | 0.538952 | 0.574403 | 0.161878 | 0.163212 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000322 |
BRD-K72951360-001-01-4 | ACH-000736 | SNU601_STOMACH | HTS002 | 1 | -0.000334 | 2.252796 | 0.835176 | 0.524604 | 0.099193 | 0.099164 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000736 |
BRD-K72951360-001-01-4 | ACH-000809 | KYSE410_OESOPHAGUS | HTS002 | 1 | 0.010582 | 1.285471 | 0.700762 | 0.593919 | 0.187114 | 0.190254 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000809 |
BRD-K72951360-001-01-4 | ACH-000747 | NCIH1703_LUNG | HTS002 | 1 | 0.014059 | 1.825237 | 0.797583 | 0.50211 | 0.074431 | 0.075603 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000747 |
BRD-K72951360-001-01-4 | ACH-000364 | U2OS_BONE | HTS002 | 1 | 0.056622 | 1.81871 | 0.596741 | 0.642487 | 0.253016 | 0.270301 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000364 |
BRD-K72951360-001-01-4 | ACH-000679 | OE19_OESOPHAGUS | HTS002 | 1 | 0.202818 | 2.232372 | 0.434286 | 0.721447 | 0.336888 | 0.425305 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000679 |
BRD-K72951360-001-01-4 | ACH-000985 | LS411N_LARGE_INTESTINE | HTS002 | 1 | -0.051501 | 0.968204 | 0.791003 | 0.699822 | 0.577903 | 0.522252 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000985 |
BRD-K72951360-001-01-4 | ACH-000441 | SH4_SKIN | HTS002 | 1 | -0.005717 | 1.361354 | 0.594438 | 0.701414 | 0.55955 | 0.554897 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000441 |
BRD-K72951360-001-01-4 | ACH-001113 | LC1SQSF_LUNG | HTS002 | 1 | -0.056466 | 1.167937 | 0.284096 | 0.78757 | 1.379622 | 1.258847 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-001113 |
BRD-K72951360-001-01-4 | ACH-000620 | JHH1_LIVER | HTS002 | 1 | 0.008297 | 103.264496 | 0.268452 | 0.883327 | 3.192824 | 3.193342 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000620 |
BRD-K72951360-001-01-4 | ACH-000853 | NCIH661_LUNG | HTS002 | 1 | 0.008936 | 3.050982 | 0.748207 | 0.668181 | 0.388125 | 0.390426 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000853 |
BRD-K72951360-001-01-4 | ACH-000102 | GMS10_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.020185 | 1.696041 | 0.771807 | 0.699214 | 0.510369 | 0.522921 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000102 |
BRD-K72951360-001-01-4 | ACH-000648 | NCIH28_PLEURA | HTS002 | 1 | 0.006552 | 6.978003 | 0.64631 | 0.708193 | 0.578215 | 0.579309 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000648 |
BRD-K72951360-001-01-4 | null | null | HTS002 | 1 | -0.00029 | 1.406435 | 0.683229 | 0.517898 | 0.092978 | 0.09294 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | false | ACH-000925_FAILED_STR |
BRD-K72951360-001-01-4 | ACH-001239 | WM2664_SKIN | HTS002 | 1 | -0.050616 | 0.625794 | 0.677607 | 0.536332 | 0.115211 | 0.098758 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-001239 |
BRD-K72951360-001-01-4 | ACH-001321 | TT_THYROID | HTS002 | 1 | 0.149099 | 4.05155 | 0.867924 | 0.746121 | 0.552794 | 0.603282 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-001321 |
BRD-K72951360-001-01-4 | ACH-000279 | EWS502_BONE | HTS002 | 1 | -0.000229 | 1.347142 | 0.664736 | 0.484894 | 0.067443 | 0.06742 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000279 |
BRD-K72951360-001-01-4 | ACH-000172 | TM87_SOFT_TISSUE | HTS002 | 1 | 0.04651 | 1.710333 | 0.756855 | 0.512088 | 0.069728 | 0.073824 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000172 |
BRD-K72951360-001-01-4 | ACH-001128 | MON_SOFT_TISSUE | HTS002 | 1 | 0.000664 | 0.834047 | 0.709342 | 0.452495 | 0.04827 | 0.048347 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-001128 |
BRD-K72951360-001-01-4 | ACH-000437 | SW1088_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.000064 | 2.474601 | 0.48314 | 0.639886 | 0.303569 | 0.303585 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000437 |
BRD-K72951360-001-01-4 | ACH-000735 | PECAPJ49_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.00488 | 3.806036 | 0.615969 | 0.557671 | 0.133873 | 0.134218 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000735 |
BRD-K72951360-001-01-4 | ACH-000643 | HDQP1_BREAST | HTS002 | 1 | 0.003609 | 0.962455 | 0.654663 | 0.602422 | 0.212673 | 0.21428 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000643 |
BRD-K72951360-001-01-4 | ACH-000207 | DETROIT562_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.084031 | 11.085434 | 0.581635 | 0.72615 | 0.549542 | 0.55874 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000207 |
BRD-K72951360-001-01-4 | ACH-000456 | BCPAP_THYROID | HTS002 | 1 | 0.002696 | 0.998726 | 0.791318 | 0.627471 | 0.273248 | 0.274731 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000456 |
BRD-K72951360-001-01-4 | ACH-000260 | SKNAS_AUTONOMIC_GANGLIA | HTS002 | 1 | 0.026091 | 7.052683 | 0.659723 | 0.699232 | 0.499435 | 0.503244 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000260 |
BRD-K72951360-001-01-4 | ACH-000019 | MCF7_BREAST | HTS002 | 1 | 0.020639 | 2.108973 | 0.620201 | 0.659641 | 0.343177 | 0.350106 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000019 |
BRD-K72951360-001-01-4 | ACH-000582 | COLO741_SKIN | HTS002 | 1 | 0.001296 | 6.247945 | 0.59355 | 0.698382 | 0.533583 | 0.533805 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000582 |
BRD-K72951360-001-01-4 | ACH-000990 | HEC108_ENDOMETRIUM | HTS002 | 1 | 0.000635 | 1.220705 | 0.648464 | 0.660869 | 0.376836 | 0.377229 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000990 |
BRD-K72951360-001-01-4 | ACH-000592 | TM31_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.271452 | 4.904902 | 0.49933 | 0.770269 | 0.468896 | 0.550039 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000592 |
BRD-K72951360-001-01-4 | ACH-000368 | SNU1105_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.01791 | 7.632887 | 0.666365 | 0.682662 | 0.434724 | 0.436806 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000368 |
BRD-K72951360-001-01-4 | ACH-000517 | SNU410_PANCREAS | HTS002 | 1 | -0.085837 | 1.381402 | 0.373409 | 0.825423 | 1.977381 | 1.763116 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000517 |
BRD-K72951360-001-01-4 | ACH-000374 | HCC1143_BREAST | HTS002 | 1 | 0.002052 | 1.624032 | 0.549967 | 0.658081 | 0.360784 | 0.361699 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000374 |
BRD-K72951360-001-01-4 | ACH-000527 | OVISE_OVARY | HTS002 | 1 | 0.015224 | 17.325146 | 0.243911 | 0.807712 | 1.503441 | 1.506127 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000527 |
BRD-K72951360-001-01-4 | ACH-000091 | OV56_OVARY | HTS002 | 1 | 0.006725 | 1.365503 | 0.789676 | 0.554795 | 0.129312 | 0.130601 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000091 |
BRD-K72951360-001-01-4 | ACH-000759 | MDAMB175VII_BREAST | HTS002 | 1 | -0.015877 | 1.438562 | 0.505036 | 0.75333 | 0.933737 | 0.913665 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000759 |
BRD-K72951360-001-01-4 | ACH-000417 | PANC0813_PANCREAS | HTS002 | 1 | 0.008723 | 1.345304 | 0.831834 | 0.655788 | 0.346738 | 0.351304 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000417 |
BRD-K72951360-001-01-4 | ACH-000308 | EFO21_OVARY | HTS002 | 1 | 0.038014 | 1.872402 | 0.734736 | 0.671009 | 0.362382 | 0.378013 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000308 |
BRD-K72951360-001-01-4 | ACH-000991 | SNU81_LARGE_INTESTINE | HTS002 | 1 | 0.031461 | 6.406004 | 0.607174 | 0.576097 | 0.143041 | 0.1445 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000991 |
BRD-K72951360-001-01-4 | ACH-000948 | 2313287_STOMACH | HTS002 | 1 | -0.000121 | 1.832194 | 0.813731 | 0.472362 | 0.059741 | 0.059733 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000948 |
BRD-K72951360-001-01-4 | ACH-000481 | NCIH2170_LUNG | HTS002 | 1 | 0.014475 | 4.524588 | 0.82767 | 0.691961 | 0.481644 | 0.484781 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000481 |
BRD-K72951360-001-01-4 | ACH-000771 | BICR56_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.029392 | 22.984248 | 0.572621 | 0.721759 | 0.619249 | 0.620883 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000771 |
BRD-K72951360-001-01-4 | ACH-000159 | OSRC2_KIDNEY | HTS002 | 1 | 0.006207 | 1.259517 | 0.592815 | 0.687601 | 0.481495 | 0.486294 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000159 |
BRD-K72951360-001-01-4 | ACH-000929 | NCIH2110_LUNG | HTS002 | 1 | 0.010785 | 1.573462 | 0.73021 | 0.517019 | 0.087572 | 0.088794 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000929 |
BRD-K72951360-001-01-4 | ACH-000118 | HUPT3_PANCREAS | HTS002 | 1 | 0.160124 | 23.514698 | 0.822847 | 0.727417 | 0.428748 | 0.435845 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000118 |
BRD-K72951360-001-01-4 | ACH-000482 | RERFLCKJ_LUNG | HTS002 | 1 | 0.001627 | 1.32202 | 0.546154 | 0.687149 | 0.484465 | 0.485662 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000482 |
BRD-K72951360-001-01-4 | ACH-000352 | HCC1428_BREAST | HTS002 | 1 | 0.042249 | 2.642398 | 0.511405 | 0.757654 | 0.858708 | 0.887883 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000352 |
BRD-K72951360-001-01-4 | ACH-000235 | PANC0403_PANCREAS | HTS002 | 1 | -0.000034 | 1.016691 | 0.337427 | 0.7526 | 0.990873 | 0.990806 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000235 |
BRD-K72951360-001-01-4 | ACH-000900 | NCIH23_LUNG | HTS002 | 1 | -0.000205 | 1.256874 | 0.757845 | 0.495981 | 0.075123 | 0.075099 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000900 |
BRD-K72951360-001-01-4 | ACH-000479 | KNS81_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | -0.056055 | 0.905225 | 0.720694 | 0.725986 | 0.775644 | 0.689736 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000479 |
BRD-K72951360-001-01-4 | ACH-000911 | NUGC3_STOMACH | HTS002 | 1 | 0.000747 | 29.558045 | 0.411823 | 0.847288 | 2.269475 | 2.269589 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000911 |
BRD-K72951360-001-01-4 | ACH-000401 | COLO800_SKIN | HTS002 | 1 | 0.001075 | 1.316105 | 0.833678 | 0.587613 | 0.182671 | 0.18297 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000401 |
BRD-K72951360-001-01-4 | ACH-000276 | HCC38_BREAST | HTS002 | 1 | 0.166785 | 8.171114 | 0.534834 | 0.633441 | 0.139937 | 0.147063 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000276 |
BRD-K72951360-001-01-4 | ACH-000724 | HT1376_URINARY_TRACT | HTS002 | 1 | 0.024275 | 6.001213 | 0.335253 | 0.703992 | 0.526573 | 0.530958 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000724 |
BRD-K72951360-001-01-4 | ACH-000092 | NCIH2452_PLEURA | HTS002 | 1 | 0.104982 | 3.605825 | 0.574268 | 0.69149 | 0.352616 | 0.376432 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000092 |
BRD-K72951360-001-01-4 | ACH-000890 | SW1271_LUNG | HTS002 | 1 | 0.031077 | 3.36042 | 0.459909 | 0.574373 | 0.140829 | 0.143544 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000890 |
BRD-K72951360-001-01-4 | null | null | HTS002 | 1 | 0.037181 | 1.114096 | 0.868196 | 0.683998 | 0.42453 | 0.45502 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | false | ACH-000539_FAILED_STR |
BRD-K72951360-001-01-4 | ACH-000800 | NCIH446_LUNG | HTS002 | 1 | 0.140691 | 14.286089 | 0.653348 | 0.730579 | 0.477132 | 0.488296 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000800 |
BRD-K72951360-001-01-4 | ACH-000899 | WM88_SKIN | HTS002 | 1 | 0.00447 | 1.21674 | 0.666927 | 0.634657 | 0.287005 | 0.289131 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000899 |
BRD-K72951360-001-01-4 | ACH-000996 | HEC251_ENDOMETRIUM | HTS002 | 1 | 0.012936 | 2.490349 | 0.446089 | 0.639291 | 0.288351 | 0.291402 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000996 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.